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Abstract Current international guidelines lack definite con-
clusions regarding repeat stool sampling for the detection of
toxigenic Clostridium difficile. We assessed the value of re-
peat sampling and compared the diagnostic yield in an epi-
demic to a non-epidemic setting. Consecutive fecal samples
obtained during two time frames were analyzed using direct
stool immunoassay toxin testing (enzyme immunoassay
[EIA]), direct stool real-time PCR toxin gene testing, and
toxigenic culture. Samples collected within 7 days of the ini-
tial sample were considered repeat tests. In the epidemic set-
ting 989 patients were analyzed, and in the non-epidemic set-
ting 1,015. In the epidemic setting 204 patients had two or
more specimens included for analysis and in the non-epidemic
setting 287 patients. In the epidemic setting 136 samples
yielded a positive results, either by EIA or toxigenic culture;
of these, 108 were positive according to EIA and 123 accord-
ing to toxigenic culture. In the first test round 98 (90.7 %,
95 % CI 85.3 to 96.2), 114 (92.7 %, 88.1 to 97.3), and 126
(92.6%, 88.3 to 97.0) positives were detected. Subsequent test
rounds yielded 10 (9.3 %, 3.8 to 14.7), 9 (7.3 %, 2.7 to 11.9),
and 10 (7.4 %, 3.0 to 11.7) extra positives. In the non-
epidemic setting EIA, toxigenic culture and PCR detected
33, 66, and 83 positives. The three tests combined 93 detected
positives. In the first test round 30 (90.9 %, 81.1 to 100.7), 63
(95.5 %, 90.4 to 110.5), 76 (91.6 %, 85.6 to 97.5), and 87
(93.5%, 88.6 to 98.5) positives were detected. Subsequent test
rounds yielded 3 (9.1 %, −0.7 to 18.9), 3 (4.5 %, −0.5 to 9.6),
7 (8.4 %, 2.5 to 14.4), and 6 (6.5 %, 1.5 to 11.4) extra posi-
tives. In conclusion, repeat testing resulted in 4.5 % to 9.3 %
extra positives. No significant difference between the settings
studied could be demonstrated. Repeat sampling and
multimodality testing may be chosen in an outbreak situation
to detect all cases, effectively controlling nosocomial spread.
Introduction
Rapid diagnosis of Clostridium difficile-associated diarrhea
(CDAD) is important for both therapeutic purposes and the
timely application of adequate infection control measures.
Several diagnostic tests for the detection of toxigenic
C. difficile are available. Bacterial culture is an important mo-
dality as it yields isolates for (ribo-)typing, but it is hampered
by the relatively long time interval before reporting results.
Immunoassays are directed to either an enzyme carried by
C. difficile (glutamate dehydrogenase) or toxins produced by
C. difficile (TcdA and TcdB). These immunoassays are more
rapid diagnostic tests, but it is well known that direct immu-
noassay testing of stool samples lacks adequate sensitivity for
the detection of toxigenic C. difficile, with a sensitivity of 60–
70 % [1–3]. Real-time polymerase chain reaction (PCR)-
based diagnosis has proved to be highly sensitive and has
become more widely available [1, 4].
Several multiple-step algorithms, with combinations of dif-
ferent diagnostic tests, have been proposed to achieve accept-
able turn-around times and adequate sensitivity [2, 5–11].
Routinely ordering repeat testing for C. difficile is generally
discouraged in a non-epidemic setting as it does not seem to
increase diagnostic yield sufficiently [10–12]. It may also lead
to more false-positive results as has been pointed out by a
* J. van Prehn
j.vanprehn@vumc.nl
1 Department of Medical Microbiology and Infection Control PK 1 X
124, VU University Medical Center, De Boelelaan 1118, 1081
HVAmsterdam, The Netherlands
Eur J Clin Microbiol Infect Dis (2015) 34:2325–2330
DOI 10.1007/s10096-015-2484-9
modelling study that assumes that test performance does not
change during repeat testing [13]. The discouragement of rou-
tine repeat testing may lead to the false assumption that there
is no value in repeat sampling at all. However, repeat testing
seems beneficial in outbreak situations in which the preva-
lence is higher [14]. This has been underlined by the 2014
ESCMID guidelines, although the level of recommendation
was graded only 3 out of 4 [11]. In the 2010 IDSA guidelines
Bthe role of repeated stool during the same episode of illness^
is defined as a research gap. In the present study, our primary
aim is to assess the value of repeat sampling for several widely
used test modalities. Our secondary aim is to compare the
diagnostic yield of repeat testing during a C. difficile hospital
epidemic and compare this with a non-epidemic setting.
Materials and methods
Specimens
The results of stool testing for C. difficile during an epidemic
and non-epidemic setting at our university hospital were ana-
lyzed. The results were prospectively entered into a database,
which was retrospectively queried. Consecutive samples tak-
en from January through December 2013 were included for
the analysis of the epidemic setting. Consecutive samples tak-
en fromApril 2014 throughMarch 2015 were included for the
non-epidemic analysis. Diagnostic tests were performed ac-
cording to our institutional protocol: stool samples were tested
directly with an immunoassay for the presence of toxins A and
B, and were tested using toxigenic culture. All stool samples
from the non-epidemic timeframe and a consecutive subset
from the epidemic timeframe (from the end of November
2013 onward) were also tested directly with real time-PCR
for toxin A and B genes. Tests that did not include all available
modalities as described above were excluded from the
analysis.
Direct toxin testing
Stool samples were tested for toxins A and B using the
VIDAS CDAB enzyme-linked fluorescence assay
(Biomérieux). Standardized samples of stool (200 μl) were
added to 1 ml of diluent and centrifuged for 5 min at 12,
300 rpm. Subsequently, 300 μl of supernatant was added to
the sample well of the CDAB kit. Based on the fluorescence,
results were reported as positive (test value≥0.37), equivocal
(≥0.13 to 0.37), and negative (<0.13).
Toxigenic culture for C. difficile
Stool samples were suspended in 95 % ethanol and incubated
for 1 h at room temperature. A sample of the suspension was
then inoculated on selective CLO agar (cycloserine
100 μg/ml, cefoxitin 8 μg/ml, and amphotericin B 2 μg/ml;
Biomérieux) and incubated for 3 days at 37 °C under anaero-
bic conditions. Suspect colonies were confirmed to be
C. difficile by matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry with the Vitek MS system
(Biomérieux). In the epidemic setting positive toxigenic cul-
ture was defined as a positive direct stool toxin testing + cul-
tured C. difficile or a cultured C. difficile isolate with positive
toxin testing of the isolate. To this end, isolates were inoculat-
ed in a chopped-meat glucose broth [15]. After 1 and 2 days of
incubation a sample of the broth was tested with the VIDAS
CDAB immunoassay for the presence of toxins A and B. In
the non-epidemic setting positive toxigenic culture was de-
fined as a positive direct stool toxin gene assay + cultured
C. difficile or a cultured C. difficile isolate with subsequent
positive toxin gene testing.
Real-time PCR
A standardized amount of stool was dissolved in
1 ml S.T.A.R.-buffer (Roche Diagnostics) and kept at
−80 °C for at least one hour. After 10 min at 100 °C, DNA
was extracted using the MagNA-Pure96 platform (Roche
Diagnostics). DNA was then amplified using a Real-Time
PCR targeting the C. difficile toxin genes cdtA and cdtB, as
previously described by de Boer et al. [16]. This PCR was
performed using the LightCycler480 platform and software
(Roche Diagnostics).
Analysis
All samples from a patient collected within 7 days of the first
sample were considered to be repeat tests. Test results of sam-
ples collected after this 7-day period were not included in the
patient level analysis. All patients were clinically suspected of
CDAD and when a positive result was reported for either test
modality, they were treated accordingly (cessation of antibiot-
ic therapy where possible and/or metronidazole or vancomy-
cin per os) and appropriate infection preventionmeasurements
were taken. The diagnostic yield of extra test rounds was




During the epidemic setting, 1,883 stool samples were taken,
of which 11 were excluded because no culture result was
available, and 4 because no direct immunoassay was avail-
able. After exclusion, there were 1,868 samples available for
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analysis of the epidemic timeframe. During the non-epidemic
setting 1,745 stool samples were taken, of which 37 were
excluded: 3 had no direct PCR and direct immunoassay on
stool available, 16 had no culture, 13 had no direct PCR on
stool, and 5 had no direct immunoassay test. After exclusion,
there were 1,708 samples available for analysis of the non-
epidemic timeframe. The results of this analysis and the over-
lap of the positive test results are shown in a Venn diagram in
Fig. 1a for the epidemic timeframe, and in Fig. 1b for the non-
epidemic timeframe [17]. In the epidemic timeframe
there were 282 samples that tested positive with either
immunoassay or toxigenic culture, 263 of which were
toxigenic culture positive; in 19 samples toxin was dem-
onstrated while C. difficile was not cultured. In the non-
epidemic timeframe there were 185 samples that tested
positive with either immunoassay, toxigenic culture, or
PCR; 60 of these samples tested positive with immuno-
assay, 169 with PCR, and 143 with toxigenic culture. In
Table 1 Number of patients















Epidemic timeframe 989 204 35 5 2 0
Non-epidemic timeframe 1,015 287 55 8 0 0
Tests were only considered to be repeat tests when samples of a patient were collected within 7 days of the first
sample
Fig. 1 Venn diagram of sample
level analysis in a the epidemic
timeframe and b the non-
epidemic timeframe. Samples
with a positive result are shown.
In the epidemic timeframe there
were 1,586 samples with both a
negative direct enzyme immuno-
assay (EIA) and toxigenic culture.
In the non-epidemic timeframe
there were 1,523 samples with a
negative direct EIA, negative di-
rect polymerase chain reaction
(PCR), and a negative toxigenic
culture (8 PCR results that were
not interpretable were regarded as
negative)
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9 samples toxin was demonstrated using immunoassay,
while C. difficile was not cultured. There were 33
stool samples in which toxin genes were demonstrated
while no toxin was detected and no C. difficile was
cultured.
Patients
In the epidemic setting, 989 patients were analyzed, and
in the non-epidemic setting 1,015 patients were analyzed.
The number of patients that were included per test round
for each timeframe can be found in Table 1. In the epi-
demic situation, 136 patients tested positive with either
toxin testing or toxigenic culture. In the non-epidemic
setting a total of 93 patients tested positive with either
toxin testing, toxigenic culture or toxin gene testing.
The diagnostic yield of repeat testing in the epidemic
situation ranged from 7.3 to 9.3 %, for detailed results
see Table 2. Subset analysis of 137 patients tested with
PCR, 30 of whom tested positive, indicated a diagnostic
yield of 10 % of repeat PCR testing in the epidemic
situation (Table 3). Repeat testing in the non-epidemic
situation resulted in a diagnostic yield ranging from
4.5 % to 9.1 %, for detailed results see Table 4. The
95 % confidence intervals of the diagnostic yield of
repeat testing showed overlapping results, indicating no
significant difference between the epidemic and non-
epidemic setting.
Discussion
In the present study we evaluated repeat C. difficile testing
using several diagnostic modalities and found that repeat sam-
pling resulted in 4.5 % to 9.3 % extra positives. We could not
demonstrate a significant difference between the epidemic and
non-epidemic settings studied. The largest increase in positive
patients was found when we used all tests on the primary
sample, compared with direct PCR only. Direct PCR testing
with repeat samples yielded a few more positive patients. The
same was true, to a lesser extent, when toxigenic culture was
added to direct PCR. The highest number of positive patients
will be detectedwithmultiplemodality testing and repeat testing.
To prevent bias caused by patient-to-patient transmission,
we have limited the interval of repeat testing and only ana-
lyzed the first episode of test series per patient. As the Venn
diagrams of the sample level analysis clearly illustrate, it is
hard to define a true gold standard when all modalities used
seem to miss some positives that are detected using other
modalities; however, Fig. 1b illustrates that PCR testing will
result in the highest detection rate of patients with a positive
immunoassay, PCR or toxigenic culture. In clinical practice
we initiated CDAD treatment and infection prevention mea-
sures if any of the tests were positive. It is of interest that of the
33 samples that only tested positive with PCR, several sam-
ples belonged to patients who tested positive with other mo-
dalities before or afterward, i.e., patients with emerging or
regressing disease. This probably indicates that the PCR is
indeed more sensitive than the other tests studied. In the
Table 3 Diagnostic yield of repeat polymerase chain reaction (PCR) in the epidemic setting
1st test 2nd test 3rd test 4th test
Test modality n npositives total npositives % (95 % CI) npositives % (95 % CI) npositives % (95 % CI) npositives
PCR 137 30 27 90.0 (79.3 to 100.7) 3 10.0 (−0.7 to 20.7) 0 0 (0 to 0) 0
Analysis of a consecutive subset tested with PCR. The number of positive patients detected is shown with the percentage diagnostic yield per test round
and 95 % confidence intervals
Table 2 Diagnostic yield of repeat testing in the epidemic setting
1st test 2nd test 3rd test 4th test 5th test
Test modality n npositives total npositives % (95 % CI) npositives % (95 % CI) npositives % (95 % CI) npositives npositives
EIA 989 108 98 90.7 (85.3 to 96.2) 10 9.3 (3.8 to 14.7) 0 0 (0 to 0) 0 0
Toxigenic culture 989 123 114 92.7 (88.1 to 97.3) 8 6.5 (2.1 to 10.9) 1 0.8 (−0.8 to 2.4) 0 0
Any of the two
modalities
989 136 126 92.6 (88.3 to 97.0) 9 6.6 (2.4 to 10.8) 1 0.7 (−0.7 to 2.2) 0 0
The number of positive patients detected by the different diagnostic modalities is shown with the percentage diagnostic yield per test round and 95 %
confidence intervals
EIA enzyme immunoassay
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present study, we have regarded equivocal EIA results as neg-
ative. Of the 63 samples with equivocal results in the non-
epidemic setting, 47 were negative with both direct PCR and
toxigenic culture, and 16 were positive with both direct PCR
and toxigenic culture. If these equivocal results were regarded
as positive, this would lead to an increase in concordance
between EIA and PCR/toxigenic culture. However, this would
also lead to an even larger increase in samples that were pos-
itive only according to EIA; these could be false-positives.
Our study has some limitations. In the epidemic setting,
only a consecutive subset of the patients received a PCR test;
however, this subset contains a considerable number of pa-
tients with a positive test. Furthermore, in the non-epidemic
setting, PCR analysis was carried out on all samples included
in the study (and no significant differences in diagnostic yield
of repeat testing with any modality was demonstrated between
the two settings). It could be argued that a multicenter study
would be necessary to externally validate our results.
However, our results are based on a commonly used and com-
mercially available immunoassay, standardized regular bacte-
rial culture techniques, and a previously described PCR
method.
Our results agree with the outcome of the study by Debast
et al., who found that repeat C. difficile toxin testing of stools
within 1 week yielded 5 % of positive patients [14]. They
concluded that repeat toxin testing of stools is of value for
controlling outbreaks of C. difficile infection. From our own
experience, we agree with this point of view. Other studies
found a lower diagnostic yield from repeat testing [12, 18].
For example, in a study by Aichinger et al. it was concluded
that repeat testing by enzyme immunoassay and PCR is of
little value, as diagnostic gains of less than 2 % were calculat-
ed [12]. Amore recent study byGreen et al. found that only 11
out of 1,066 PCR tests repeated within 7 days (1 %) were
positive [18]. When taking into account the costs of routinely
ordering repeat testing and the low diagnostic yield, it seems
inadvisable to routinely apply repeat testing in the non-
epidemic setting [19].
As pointed out in a paper by Peterson and Robicsek, there
is a risk of more false-positives with repeat sampling,
assuming that test performance does not change with repeat
sampling [13]. However, in clinical practice repeat testing is
ordered, especially in patients with continuing clinical suspi-
cion of CDAD, thereby altering the a priori chance of a pos-
itive test result, which affects test characteristics and subse-
quently diagnostic yield. Although we could not demonstrate
a statistically significant difference in the diagnostic yield of
repeat testing between the two settings, the absolute diagnos-
tic yield in the epidemic setting will be higher by definition.
Furthermore, in an outbreak situation it is paramount to have
the highest sensitivity possible and to find every CDAD case.
To this end, it might be better to accept more false-positives
and apply repeat sampling and multimodality testing to in-
crease sensitivity and effectively control nosocomial spread.
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